Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer
NCT07227025Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of amivantamab, olomorasib in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
amivantamabolomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07227025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227025.